Effect of an aldose reductase inhibitor on alveolar bone loss associated with periodontitis in diabetic rats

Peter F Kador, Tomofumi Hamada, Richard A Reinhardt, Karen Blessing

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Periodontitis is a lesser known but frequent complication of diabetes mellitus and is the major cause of tooth loss in patients with diabetes. Dental therapy for this complication is primarily focused on the control of oral infections. No current therapy directly addresses the potential effects of diabetes itself on this complication. In studies conducted in young normal control and streptozotocin diabetic rats (100 g) treated with and without the aldose reductase inhibitor (ARI) imirestat, experimental periodontitis was induced in one side of the mouth by 3 injections of lipopolysaccharide (LPS) from Escherichia coli 055:B5 9 into the palatal gingiva between the first and second maxillary molars at 48-hour intervals. The other control side was injected with phosphate buffered saline (PBS). Fourteen days after the final injection, all rats were euthanized and the heads were defleshed. The maxillary area was separated from the remaining skull. The cleaned maxillary alveoli were stained in 5% aqueous toluidine blue to identify the cemento-enamel junction (CEJ) on the molars. Alveolar bone loss was measured according to standard methods by determining both the distance between the CEJ and the alveolar bone on the 2 molars between which the injections were made, and by measuring the ratio of root area/enamel area in the same region. These measurements showed that LPS injections resulted in significant bone loss compared with PBS injections in both control and diabetic rats, and that this bone loss was not present in the ARI-treated diabetic rats (P < 0.05). These results suggest that the sorbitol pathway plays a critical role in the pathophysiological mechanism(s) of diabetic periodontitis and that AR may be a direct pharmacological target for the treatment for this disease.

Original languageEnglish (US)
Pages (from-to)138-144
Number of pages7
JournalPostgraduate Medicine
Volume122
Issue number3
DOIs
StatePublished - May 1 2010

Fingerprint

Alveolar Bone Loss
Aldehyde Reductase
Periodontitis
Dental Enamel
Injections
Bone and Bones
Lipopolysaccharides
Phosphates
Tooth Loss
Tolonium Chloride
Sorbitol
Gingiva
Diabetes Complications
Streptozocin
Infection Control
Skull
Mouth
Tooth
Therapeutics
Head

Keywords

  • Alveolar bone loss
  • Diabetes
  • Periodontitis
  • Rat study
  • Sorbitol pathway

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effect of an aldose reductase inhibitor on alveolar bone loss associated with periodontitis in diabetic rats. / Kador, Peter F; Hamada, Tomofumi; Reinhardt, Richard A; Blessing, Karen.

In: Postgraduate Medicine, Vol. 122, No. 3, 01.05.2010, p. 138-144.

Research output: Contribution to journalArticle

@article{c53e1b832ad043bb8e5ed73f21704525,
title = "Effect of an aldose reductase inhibitor on alveolar bone loss associated with periodontitis in diabetic rats",
abstract = "Periodontitis is a lesser known but frequent complication of diabetes mellitus and is the major cause of tooth loss in patients with diabetes. Dental therapy for this complication is primarily focused on the control of oral infections. No current therapy directly addresses the potential effects of diabetes itself on this complication. In studies conducted in young normal control and streptozotocin diabetic rats (100 g) treated with and without the aldose reductase inhibitor (ARI) imirestat, experimental periodontitis was induced in one side of the mouth by 3 injections of lipopolysaccharide (LPS) from Escherichia coli 055:B5 9 into the palatal gingiva between the first and second maxillary molars at 48-hour intervals. The other control side was injected with phosphate buffered saline (PBS). Fourteen days after the final injection, all rats were euthanized and the heads were defleshed. The maxillary area was separated from the remaining skull. The cleaned maxillary alveoli were stained in 5{\%} aqueous toluidine blue to identify the cemento-enamel junction (CEJ) on the molars. Alveolar bone loss was measured according to standard methods by determining both the distance between the CEJ and the alveolar bone on the 2 molars between which the injections were made, and by measuring the ratio of root area/enamel area in the same region. These measurements showed that LPS injections resulted in significant bone loss compared with PBS injections in both control and diabetic rats, and that this bone loss was not present in the ARI-treated diabetic rats (P < 0.05). These results suggest that the sorbitol pathway plays a critical role in the pathophysiological mechanism(s) of diabetic periodontitis and that AR may be a direct pharmacological target for the treatment for this disease.",
keywords = "Alveolar bone loss, Diabetes, Periodontitis, Rat study, Sorbitol pathway",
author = "Kador, {Peter F} and Tomofumi Hamada and Reinhardt, {Richard A} and Karen Blessing",
year = "2010",
month = "5",
day = "1",
doi = "10.3810/pgm.2010.05.2151",
language = "English (US)",
volume = "122",
pages = "138--144",
journal = "Postgraduate Medicine",
issn = "0032-5481",
publisher = "Medquest Communications LLC",
number = "3",

}

TY - JOUR

T1 - Effect of an aldose reductase inhibitor on alveolar bone loss associated with periodontitis in diabetic rats

AU - Kador, Peter F

AU - Hamada, Tomofumi

AU - Reinhardt, Richard A

AU - Blessing, Karen

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Periodontitis is a lesser known but frequent complication of diabetes mellitus and is the major cause of tooth loss in patients with diabetes. Dental therapy for this complication is primarily focused on the control of oral infections. No current therapy directly addresses the potential effects of diabetes itself on this complication. In studies conducted in young normal control and streptozotocin diabetic rats (100 g) treated with and without the aldose reductase inhibitor (ARI) imirestat, experimental periodontitis was induced in one side of the mouth by 3 injections of lipopolysaccharide (LPS) from Escherichia coli 055:B5 9 into the palatal gingiva between the first and second maxillary molars at 48-hour intervals. The other control side was injected with phosphate buffered saline (PBS). Fourteen days after the final injection, all rats were euthanized and the heads were defleshed. The maxillary area was separated from the remaining skull. The cleaned maxillary alveoli were stained in 5% aqueous toluidine blue to identify the cemento-enamel junction (CEJ) on the molars. Alveolar bone loss was measured according to standard methods by determining both the distance between the CEJ and the alveolar bone on the 2 molars between which the injections were made, and by measuring the ratio of root area/enamel area in the same region. These measurements showed that LPS injections resulted in significant bone loss compared with PBS injections in both control and diabetic rats, and that this bone loss was not present in the ARI-treated diabetic rats (P < 0.05). These results suggest that the sorbitol pathway plays a critical role in the pathophysiological mechanism(s) of diabetic periodontitis and that AR may be a direct pharmacological target for the treatment for this disease.

AB - Periodontitis is a lesser known but frequent complication of diabetes mellitus and is the major cause of tooth loss in patients with diabetes. Dental therapy for this complication is primarily focused on the control of oral infections. No current therapy directly addresses the potential effects of diabetes itself on this complication. In studies conducted in young normal control and streptozotocin diabetic rats (100 g) treated with and without the aldose reductase inhibitor (ARI) imirestat, experimental periodontitis was induced in one side of the mouth by 3 injections of lipopolysaccharide (LPS) from Escherichia coli 055:B5 9 into the palatal gingiva between the first and second maxillary molars at 48-hour intervals. The other control side was injected with phosphate buffered saline (PBS). Fourteen days after the final injection, all rats were euthanized and the heads were defleshed. The maxillary area was separated from the remaining skull. The cleaned maxillary alveoli were stained in 5% aqueous toluidine blue to identify the cemento-enamel junction (CEJ) on the molars. Alveolar bone loss was measured according to standard methods by determining both the distance between the CEJ and the alveolar bone on the 2 molars between which the injections were made, and by measuring the ratio of root area/enamel area in the same region. These measurements showed that LPS injections resulted in significant bone loss compared with PBS injections in both control and diabetic rats, and that this bone loss was not present in the ARI-treated diabetic rats (P < 0.05). These results suggest that the sorbitol pathway plays a critical role in the pathophysiological mechanism(s) of diabetic periodontitis and that AR may be a direct pharmacological target for the treatment for this disease.

KW - Alveolar bone loss

KW - Diabetes

KW - Periodontitis

KW - Rat study

KW - Sorbitol pathway

UR - http://www.scopus.com/inward/record.url?scp=77953110511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953110511&partnerID=8YFLogxK

U2 - 10.3810/pgm.2010.05.2151

DO - 10.3810/pgm.2010.05.2151

M3 - Article

VL - 122

SP - 138

EP - 144

JO - Postgraduate Medicine

JF - Postgraduate Medicine

SN - 0032-5481

IS - 3

ER -